Maher-Edwards G, De'Ath J, Barnett C, Lavrov A, Lockhart A (2015)
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease
Alzheimers Dement (N Y) 1: 131

Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C (2014)
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study
Atherosclerosis 235: 384

Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, Magee M, Lepore JJ, Sprecher DL (2014)
Platelet aggregation unchanged by lipoprotein-associated phospholipase A inhibition: results from an in vitro study and two randomized phase I trials
PLoS ONE 9: e83094

Tawakol A, Singh P, Rudd JH, Soffer J, Cai G, Vucic E, Brannan SP, Tarka EA, Shaddinger BC, Sarov-Blat L, Matthews P, Subramanian S, Farkouh M, Fayad ZA (2014)
Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging
J Am Coll Cardiol 63: 86

Davidson JE, Lockhart A, Amos L, Stirnadel-Farrant HA, Mooser V, Sollberger M, Regeniter A, Monsch AU, Irizarry MC (2012)
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study
Alzheimers Res Ther 4: 51

Wilensky RL, Macphee CH (2009)
Lipoprotein-associated phospholipase A(2) and atherosclerosis
Curr Opin Lipidol 20: 415